Cart
sales@molnova.com
Lepidiline C
CAS No. 2750933-59-4
Lepidiline C( —— )
Catalog No. M36079 CAS No. 2750933-59-4
Lepidiline C is a novel imidazoles alkaloids extracted from the root of Lepidium meenii Walpers of the brassaceae family. It has shown cytotoxic activity against HL-60 cells (IC50:27.7 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 76 | Get Quote |
|
| 5MG | 113 | Get Quote |
|
| 10MG | 187 | Get Quote |
|
| 25MG | 302 | Get Quote |
|
| 50MG | 434 | Get Quote |
|
| 100MG | 578 | Get Quote |
|
| 200MG | 779 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLepidiline C
-
NoteResearch use only, not for human use.
-
Brief DescriptionLepidiline C is a novel imidazoles alkaloids extracted from the root of Lepidium meenii Walpers of the brassaceae family. It has shown cytotoxic activity against HL-60 cells (IC50:27.7 μM).
-
DescriptionLepidiline C shows cytotoxic activity against HL-60 cells with an IC50 of 27.7 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2750933-59-4
-
Formula Weight342.86
-
Molecular FormulaC20H23ClN2O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (291.66 mM; Ultrasonic )
-
SMILES[Cl-].COc1cccc(Cn2c[n+](Cc3ccccc3)c(C)c2C)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mlostoń G, et al. Synthesis and Cytotoxic Activity of Lepidilines A-D: Comparison with Some 4,5-Diphenyl Analogues and Related Imidazole-2-thiones. J Nat Prod. 2021 Nov 22. ?
molnova catalog
related products
-
Myrrhone
Myrrhone is a natural product.
-
Phenolphthalein
An acid-base indicator which is colorless in acid solution, but turns pink to red as the solution becomes alkaline. It is used medicinally as a cathartic.
-
Clivatuzumab
Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.
